Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
26,582,727
-
Share change
-
+22,261,213
-
Total reported value
-
$257,486,000
-
Price per share
-
$9.68
-
Number of holders
-
67
-
Value change
-
+$215,656,341
-
Number of buys
-
63
-
Number of sells
-
1
Institutional Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q1 2017
As of 31 Mar 2017,
AVADEL PHARMACEUTICALS - COM (AVDL) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,582,727 shares.
The largest 10 holders included
Broadfin Capital, LLC, DEERFIELD MANAGEMENT CO, JANUS CAPITAL MANAGEMENT LLC, Bank of New York Mellon Corp, ACADIAN ASSET MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, DEUTSCHE BANK AG\, J. Goldman & Co LP, BROWN CAPITAL MANAGEMENT LLC, and ARMISTICE CAPITAL, LLC.
This page lists
68
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.